ESC 2019 | SYNTAXES: Ten-Year Outcomes!

The SYNTAXES (SYNTAX Extended Survival) was presented at ESC 2019 with somewhat unexpected results in favor of PCI. This is why the SYNTAX continues to be one of the best studies interventional cardiologists can rely on.

The original SYNTAX tested mortality (primary end point) with PCI vs. CABG in patients with multivessel and/or left main disease. After the SYNTAX, several randomized studies have followed suit, using more modern stents, intravascular imaging and coronary physiology to decide for or against PCI.

There has been a debate about long-term outcomes, seeing as, in theory, CABG would have greater benefits. The SYNTAXES is the first large randomized study to provide us with unique ten- year outcomes for PCI (at least in terms of mortality). It is worth noting that a remarkable 94% of the population was able to complete follow up.


Read also: ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.


Results showed the equivalence in primary end point (all-cause mortality) between PCI and CABG (27% PCI and 23.5% CABG; p=0.092). There were no differences in patients with left main disease (26.1% PCI and 26.7% CABG; p=0.47) or diabetis (34.2% PCI and 32.1% CABG, p=0.56).

However, there was a difference in survival in favor of CABG in patients with three-vessel disease (27.7% PCI and 20.6% CABG, p=0.006). This difference was driven by patients with SYNTAX score >33. It does not come as a surprise and, for years now, we have known the SYNTAX >33 are not for interventional cardiologists, unless there is CABG counterindication.

These outcomes provide us with the foundation to further PCI, especially in the treatment of diabetics (despite the FREEDOM), and patients with left main disease and three-vessel disease with low or intermediate SYNTAX score.

All this in the context of a stent that has been discontinued and that has clearly been surpassed by the new generation devices (even though we seem to have reached a plateau). Furthermore, there are now more potent antiplatelet agents, coronary physiology to make better informed decisions and intravascular imaging to optimize outcomes.

Original title: Ten-year survival after coronary artery bypass grafting vs PCI: the SYNTAX Extended Survival study.

Reference: Presentado por Daniel Johannes en el ESC 2019. Paris, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....